Anlotinib Plus Docetaxel vs Docetaxel for 2nd-Line Treatment of EGFR negative NSCLC (ALTER-L018): A Randomized Phase II Trial
JOURNAL OF THORACIC ONCOLOGY(2021)
关键词
Anlotinib, EGFR wild-type NSCLC, Second-line therapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要